WO2007030451A3 - Anticorps utilises comme mimetiques de recepteurs de lymphocytes t, leurs methodes de production et leurs applications - Google Patents

Anticorps utilises comme mimetiques de recepteurs de lymphocytes t, leurs methodes de production et leurs applications Download PDF

Info

Publication number
WO2007030451A3
WO2007030451A3 PCT/US2006/034547 US2006034547W WO2007030451A3 WO 2007030451 A3 WO2007030451 A3 WO 2007030451A3 US 2006034547 W US2006034547 W US 2006034547W WO 2007030451 A3 WO2007030451 A3 WO 2007030451A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
antibodies
mhc
cell receptor
interest
Prior art date
Application number
PCT/US2006/034547
Other languages
English (en)
Other versions
WO2007030451A2 (fr
Inventor
Jon A Weidanz
Vaughan Wittman
Original Assignee
Receptor Logic Ltd
Jon A Weidanz
Vaughan Wittman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Receptor Logic Ltd, Jon A Weidanz, Vaughan Wittman filed Critical Receptor Logic Ltd
Priority to EP06814164A priority Critical patent/EP1933864A4/fr
Priority to CA002662798A priority patent/CA2662798A1/fr
Priority to AU2006289683A priority patent/AU2006289683A1/en
Publication of WO2007030451A2 publication Critical patent/WO2007030451A2/fr
Priority to IL190014A priority patent/IL190014A0/en
Publication of WO2007030451A3 publication Critical patent/WO2007030451A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne une méthode permettant de produire des anticorps qui reconnaissent des peptides associés à un état oncogène ou pathologique, les peptides se présentant dans le contexte de molécules HLA. Ces anticorps produisent un effet semblable à la spécificité d'un récepteur des lymphocytes T (TCR), mais possèdent une affinité de liaison supérieure, ce qui signifie que les molécules peuvent être utilisées comme réactifs dans des applications thérapeutiques et diagnostiques et dans la recherche. La méthode de la présente invention destinée à la production d'un mimétique de récepteur de lymphocytes T consiste à identifier un peptide d'intérêt capable d'être présenté par une molécule CMH, à former un immunogène comprenant au moins un complexe peptide/CMH dont le peptide est le peptide d'intérêt, puis à administrer une dose utile de l'immunogène à un hôte pour déclencher une réaction immunitaire et à analyser le sérum prélevé chez l'hôte pour déterminer si les anticorps désirés qui reconnaissent une présentation tridimensionnelle du peptide dans le sillon de fixation de la molécule CMH sont produits. Ces anticorps désirés peuvent différencier le complexe peptide/CMH par rapport à une molécule CMH seule, le peptide seul, et un complexe formé par un CMH et un peptide sans intérêt. La méthode de l'invention consiste enfin à isoler les anticorps désirés.
PCT/US2006/034547 2005-09-07 2006-09-07 Anticorps utilises comme mimetiques de recepteurs de lymphocytes t, leurs methodes de production et leurs applications WO2007030451A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP06814164A EP1933864A4 (fr) 2005-09-07 2006-09-07 Anticorps utilisés comme mimétiques de récepteurs de lymphocytes t, leurs méthodes de production et leurs applications
CA002662798A CA2662798A1 (fr) 2005-09-07 2006-09-07 Anticorps utilises comme mimetiques de recepteurs de lymphocytes t, leurs methodes de production et leurs applications
AU2006289683A AU2006289683A1 (en) 2005-09-07 2006-09-07 Antibodies as T cell receptor mimics, methods of production and uses thereof
IL190014A IL190014A0 (en) 2005-09-07 2008-03-06 Antibodies as t cell receptor mimics, methods of production and uses thereof

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US71462105P 2005-09-07 2005-09-07
US60/714,621 2005-09-07
US75154205P 2005-12-19 2005-12-19
US60/751,542 2005-12-19
US75273705P 2005-12-20 2005-12-20
US60/752,737 2005-12-20
US83827606P 2006-08-17 2006-08-17
US60/838,276 2006-08-17

Publications (2)

Publication Number Publication Date
WO2007030451A2 WO2007030451A2 (fr) 2007-03-15
WO2007030451A3 true WO2007030451A3 (fr) 2009-04-16

Family

ID=37836380

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/034547 WO2007030451A2 (fr) 2005-09-07 2006-09-07 Anticorps utilises comme mimetiques de recepteurs de lymphocytes t, leurs methodes de production et leurs applications

Country Status (5)

Country Link
EP (1) EP1933864A4 (fr)
AU (1) AU2006289683A1 (fr)
CA (1) CA2662798A1 (fr)
IL (1) IL190014A0 (fr)
WO (1) WO2007030451A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007254859A1 (en) * 2006-06-01 2007-12-13 Receptor Logic, Ltd Antibodies as T cell receptor mimics, methods of production and uses thereof
WO2009108372A2 (fr) * 2008-02-27 2009-09-03 Receptor Logic, Inc. Anticorps imitant les récepteurs des lymphocytes t, leurs procédés de production et d’utilisation
UA114108C2 (uk) 2012-07-10 2017-04-25 Борд Оф Ріджентс, Дзе Юніверсіті Оф Техас Сістем Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679641A (en) * 1992-05-26 1997-10-21 Rijksuniversiteit Leiden Peptides of human P53 protein for use in human T cell response inducing compositions, and human P53 protein-specific cytotoxic t-lymphocytes
US5726023A (en) * 1993-03-17 1998-03-10 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
US5968513A (en) * 1996-06-24 1999-10-19 University Of Maryland Biotechnology Institute Method of promoting hematopoiesis using derivatives of human chorionic gonadotropin
US20030165513A1 (en) * 2000-12-04 2003-09-04 Venky Ramakrishna Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US20030223994A1 (en) * 2002-02-20 2003-12-04 Hoogenboom Henricus Renerus Jacobus Mattheus MHC-peptide complex binding ligands
US20040191260A1 (en) * 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
WO2004101607A2 (fr) * 2003-05-13 2004-11-25 Hildebrand William H Representation cartographique comparative de ligands a partir de cellules positives de classe i du cmh

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1319184B1 (fr) * 2000-08-14 2007-07-25 N.V. Organon Utilisation d'anticorps contre des complexes de peptides mhc specifiques
FR2839452A1 (fr) * 2002-05-07 2003-11-14 Pf Medicament Utilisation de peptide derive de la sous-unite beta de l'hcg pour generer une reponse de type ctl antitumorale
US20060034850A1 (en) * 2004-05-27 2006-02-16 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679641A (en) * 1992-05-26 1997-10-21 Rijksuniversiteit Leiden Peptides of human P53 protein for use in human T cell response inducing compositions, and human P53 protein-specific cytotoxic t-lymphocytes
US5726023A (en) * 1993-03-17 1998-03-10 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
US5968513A (en) * 1996-06-24 1999-10-19 University Of Maryland Biotechnology Institute Method of promoting hematopoiesis using derivatives of human chorionic gonadotropin
US20030165513A1 (en) * 2000-12-04 2003-09-04 Venky Ramakrishna Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US20030223994A1 (en) * 2002-02-20 2003-12-04 Hoogenboom Henricus Renerus Jacobus Mattheus MHC-peptide complex binding ligands
US20040191260A1 (en) * 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
WO2004101607A2 (fr) * 2003-05-13 2004-11-25 Hildebrand William H Representation cartographique comparative de ligands a partir de cellules positives de classe i du cmh

Also Published As

Publication number Publication date
AU2006289683A1 (en) 2007-03-15
IL190014A0 (en) 2008-08-07
CA2662798A1 (fr) 2007-03-15
EP1933864A4 (fr) 2009-12-16
WO2007030451A2 (fr) 2007-03-15
EP1933864A2 (fr) 2008-06-25

Similar Documents

Publication Publication Date Title
WO2005116072A3 (fr) Anticorps mimetiques de recepteurs de cellules t et leurs procedes de production et d'utilisation
US11092601B2 (en) Methods for detecting peptide/MHC/TCR binding
Bharadwaj et al. Drug hypersensitivity and human leukocyte antigens of the major histocompatibility complex
CA2972306C (fr) Procede permettant la quantification absolue des peptides contre le cancer restreints aux molecules hla traites naturellement
Agaton et al. Affinity proteomics for systematic protein profiling of chromosome 21 gene products in human tissues
Schirle et al. Combining computer algorithms with experimental approaches permits the rapid and accurate identification of T cell epitopes from defined antigens
CA2793490A1 (fr) Differenciation quantitative de peptides a restriction hla traites naturellement dans le but de developper une immunotherapie pour les cancers, les maladies auto-immunes et les maladies infectieuses
Shahine et al. A T-cell receptor escape channel allows broad T-cell response to CD1b and membrane phospholipids
NZ584558A (en) Peptide-lipid constructs and their use in diagnostic and therapeutic applications
Dørum et al. HLA-DQ molecules as affinity matrix for identification of gluten T cell epitopes
Archila et al. Grass‐specific CD 4+ T‐cells exhibit varying degrees of cross‐reactivity, implications for allergen‐specific immunotherapy
Fulton et al. Immunoproteomics: current technology and applications
Sollid et al. Small bowel, celiac disease and adaptive immunity
CN112739708A (zh) 对与主要组织相容性复合体结合的肽进行单分子测序
WO2007030451A3 (fr) Anticorps utilises comme mimetiques de recepteurs de lymphocytes t, leurs methodes de production et leurs applications
Chen et al. Identification of critical amino acids in an immunodominant IgE epitope of Pen c 13, a major allergen from Penicillium citrinum
Gengenbacher et al. Mycobacterium tuberculosis in the Proteomics Era
Stražar et al. HLA-II immunopeptidome profiling and deep learning reveal features of antigenicity to inform antigen discovery
ES2463828T3 (es) Polipéptidos híbridos hipoalergénicos para el tratamiento de alergia
Wang et al. Recent progress on MHC-I epitope prediction in tumor immunotherapy
Inoue et al. Discovery of an α2, 9-polyNeu5Ac glycoprotein in C-1300 murine neuroblastoma (clone NB41A3)
Wahl et al. Direct class I HLA antigen discovery to distinguish virus-infected and cancerous cells
WO2022133347A2 (fr) Exposition de peptide-mhc (pmhc) sur des échafaudages protéiques multimères et leurs utilisations
WO2006138449A3 (fr) Procede d'identification d'un antigene de cellules auxiliaires associe a des tumeurs dependant du cmh de classe 2
Stenvall et al. High-throughput solubility assay for purified recombinant protein immunogens

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 190014

Country of ref document: IL

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006289683

Country of ref document: AU

Ref document number: 2006814164

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006289683

Country of ref document: AU

Date of ref document: 20060907

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2662798

Country of ref document: CA